Biomea Fusion, Inc. has announced a strategic realignment to focus on its core programs in diabetes and obesity, specifically advancing icovamenib and BMF-650, while cutting costs to extend its cash ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results